Tanios S. Bekaii-Saab, MD, on Genomic Drivers in Cholangiocarcinoma at ASCO 2021

Video

At the 2021 American Society of Clinical Oncology Annual Meeting, CancerNetwork® spoke with Tanios S. Bekaii-Saab, MD, about genomic drivers in cholangiocarcinoma.

At the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting, CancerNetwork® spoke with Tanios S. Bekaii-Saab, MD, about genomic drivers in cholangiocarcinoma. Notably, cholangiocarcinoma is a genomically diverse disease, with 2 main drivers that have current FDA-approved targeted agents.

Transcript:

Biliary tract cancers are very interesting, especially intrahepatic cholangiocarcinoma; we are seeing more of this strictly [in] extrahepatic cholangiocarcinoma [and] even gallbladder. This disease is so anatomically diverse, but also genomically very diverse. We just recently started to break down the disease by site [and], more importantly, by genomic driver. In intrahepatic cholangiocarcinoma, there are 2 main drivers that we know of that now have either a drug [approval] or [one that is] on its way to possibly being approved.

For FGFR fusions, we know now that we have 2 agents approved. That [represents] about 10% to 15% of all patients with intrahepatic cholangiocarcinoma. To put that again in perspective, we are talking about 3000 to 5000 patients a year in the United States. That is a rare patient population that we are splitting into pieces. The FGFR-targeted agents are pemigatinib [Pemazyre] and infigratinib [(Truseltiq); those are the 2 drugs] approved for that space. Now, it turns out that there is another target that is very interesting, [which] is essentially an IDH mutation. Without really going through a lot of the biology, IDH1/2 is a key enzyme in cellular metabolism epigenetic regulation.

Reference

Makawita S, Borad MJ, Carapeto F, et al. IDH1 and IDH2 driven intrahepatic cholangiocarcinoma (IHCC): a comprehensive genomic and immune profiling study. J Clin Oncol. 2021;39(suppl 15):4009. doi:10.1200/JCO.2021.39.15_suppl.4009

Related Videos
Those with CML should discuss adverse effects such as nausea or fatigue with their providers to help optimize their quality of life during treatment.
Patients with CML can become an active part of their treatment plan by discussing any questions that come to mind with their providers.
Jorge E. Cortes, MD, emphasizes proper communication between patients with chronic myeloid leukemia and their providers during the treatment course.
Dietary interventions or other medications may help mitigate diarrhea in patients who undergo therapy for chronic myeloid leukemia.
Whether CAR T-cell therapy or T-cell engagers should dominate the multiple myeloma landscape may be hard to determine, says David S. Siegel, MD.
Next steps for research in the multiple myeloma space may include the development of novel CAR T-cell strategies and bispecific antibodies.
Ongoing research may clarify the potential benefit of avelumab when administered in combination with other agents in advanced urothelial carcinoma.
Spatial analyses may help determine factors that influence responses to sacituzumab govitecan-containing regimens in urothelial carcinoma.
Adverse effects associated with oral azacitidine in low- or intermediate-risk MDS are typically transient, according to Mikkael A. Sekeres, MD, MS.
Attending educational sessions may help with understanding how to manage toxicities associated with enfortumab vedotin in rare genitourinary cancers.
Related Content